dwarfism

BridgeBio preps approval push for dwarfism drug after ph. 3 win

BridgeBio is hoping infigratinib will get another shot at approval after the medicine hit the key goals of a phase 3 study in a form of dwarfism in children.

James Waldron Feb 12, 2026 7:30am

FDA delays decision on Ascendis' dwarfism prospect by 3 months

Nov 26, 2025 9:45am

Graphic image of an arrow nailing the bullseye of a target

Ascendis' dwarfism drug hits in phase 3, threatens BioMarin

Sep 17, 2024 9:36am

Sanofi will drop dwarfism drug as part of rare disease clear-out

Jul 25, 2024 7:58am

BridgeBio posts BioMarin-beating data on dwarfism drug prospect

Jun 4, 2024 7:30am

Drug lengthens limb bones in Robinow syndrome

Feb 17, 2023 4:01pm